To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Very long-chain acyl-coenzyme A dehydrogenase deficiency
Additional recommended knowledgeVery long-chain acyl-coenzyme A dehydrogenase deficiency is a fatty acid oxidation disorder which prevents the body from converting certain fats to energy, particularly during periods without food. Those affected by this disorder have inadequate levels of an enzyme that breaks down a group of fats called very long-chain fatty acids. DiagnosisTypically, initial signs and symptoms of this disorder occur during infancy and include low blood sugar (hypoglycemia), lack of energy (lethargy), and muscle weakness. There is also a high risk of complications such as liver abnormalities and life-threatening heart problems. Symptoms that begin later in childhood, adolescence, or adulthood tend to be milder and usually do not involve heart problems. Episodes of very long-chain acyl-coenzyme A dehydrogenase deficiency can be triggered by periods of fasting, illness, and exercise. Genetics
Mutations in the ACADVL gene lead to inadequate levels of an enzyme called very long-chain acyl-coenzyme A (CoA) dehydrogenase. Without this enzyme, very long-chain fatty acids from food and fats stored in the body cannot be degraded and processed. As a result, these fatty acids are not converted into energy, which can lead to characteristic signs and symptoms of this disorder, such as lethargy and hypoglycemia. Levels of very long-chain fatty acids or partially degraded fatty acids may build up in tissues and can damage the heart, liver, and muscles, causing more serious complications. |
||||
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Very_long-chain_acyl-coenzyme_A_dehydrogenase_deficiency". A list of authors is available in Wikipedia. |
- Diamond-Blackfan_anemia
- Novartis: FDA akzeptiert Antrag auf Erweiterung der Zulassung für Menveo
- Toepffer Lab Systems - Göppingen, Germany
- Drug shown to reverse radioiodine resistance in some advanced thyroid cancers - Memorial Sloan-Kettering will lead phase III trial of investigational drug
- Measles-Based Vector Vaccine Protects Mice against Influenza A (H7N9) Virus - Highly pathogenic avian influenza viruses such as the influenza A virus subtype H7N9 could potentially cause future influenza pandemics